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Abstract: 
Mycobacterium tuberculosis is the causative agent of the disease, tuberculosis and H37Rv is the most studied clinical strain. We use 
comparative genome analysis of Mycobacterium tuberculosis H37Rv and human for the identification of potential targets dataset. We 
used DEG (Database of Essential Genes) to identify essential genes in the H37Rv strain. The analysis shows that 628 of the 3989 
genes in Mycobacterium tuberculosis H37Rv were found to be essential of which 324 genes lack similarity to the human genome. 
Subsequently hypothetical proteins were removed through manual curation. This further resulted in a dataset of 135 proteins with 
essential function and no homology to human.  
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Background: 
Mycobacterium tuberculosis (Mtb), the causative agent of 
tuberculosis (TB), remains a major health threat. Each year, 8 
million new TB cases appear and 2 million individuals die of TB 
[1]. Moreover, it is estimated that one third of the population is 
latently infected with Mtb, of which ~10% will develop active 
disease during lifetime. The development of active TB occurs 
when the balance between natural immunity and the pathogen 
changes (e.g. upon waning of protective immune response during 
adolescence and in HIV patients [2]). Further, about half a 
million new multi-drug resistant TB cases are estimated to occur 
every year [3]. The existing drugs, although of immense value in 
controlling the disease to the extent that is being done today, 
have several shortcomings, the most important of them being the 
emergence of drug resistance rendering even the front-line drugs 
inactive. In addition, drugs such as rifampin have high levels of 
adverse effects making them prone for patient incompliance. 
Another important problem with most of the existing anti-
mycobacterials, is their inability to act upon latent forms of the 
bacillus. In addition to these problems, the vicious interactions 
between the human immunodeficiency virus and TB have led to 
further challenges for anti-tubercular drug discovery [4]. 
 
The cost of research and development in the pharmaceutical 
industry has been rising steeply and steadily in the last decade, 
but the amount of time required for bringing a new product to 
market remains around ten to fifteen years [5]. This problem has 
been labeled as an ‘‘innovation gap,’’ and it necessitates 
investment in inexpensive technologies that shorten the length of 
time spent in drug discovery. As drug discovery efforts are 
increasingly becoming rational and much less dependent on trial 
and error, identification of appropriate targets becomes a 
fundamental pre-requisite. As with all the other steps in drug 
discovery, this stage is complicated by the fact that the identified 
drug target must satisfy a variety of criteria to permit progression 
to the next stage. Important factors in this context include 
homology between target and host (to prevent host toxicity such 
homology must be low or nonexistent [6]), activity of the target 
in the diseased state [7] and the essentiality of the target to the 
pathogen’s growth and survival. Finding new targets can 
enhance the discovery process as well as solve the problem of 
drug resistance. 
 
Traditionally, targets have been identified through established 
knowledge of individual protein molecules and their functions, 
where their function has been well-characterized. Here, we use 
comparative genomics for the identification of potential targets 
for Mtb. These methods have the advantage of speed, low cost 
and even more importantly, provide a systems view of the whole 
microbe at a time, which enables asking questions that are often 
difficult to address experimentally. Drug discovery has witnessed 
a paradigm shift from the traditional medicinal chemistry-based 
ligand-oriented discovery approaches to rational drug target 
identification and target-driven lead discovery, by targeting the 
molecular mechanisms of the disease.  
 
Methodology: 
Searching for the M. tuberculosis H37Rv complete genes 
The complete genome sequence of M. tuberculosis H37Rv was 
downloaded using National Center for Biotechnology 
Information FTP server (www.ncbi.nlm.nih.gov/FTP).  
 
Comparative analysis with human 
The protein coding genes from M. tuberculosis H37Rv genome 
were subjected to BLAST against DEG 
(http://tubic.tju.edu.cn/deg) to find out the essential genes. The 
essential genes obtained after DEG search were compared with 
human genes using BLASTX. Genes which lack the homology 
with human were considered as potential drug target candidates 
for further drug development process.  
 
Functional analysis using UNIPROT 
The obtained targets genes were further analyzed by UNIPROT 
(www.uniprot.org) database to find out their functions. 
 
Results: 
Available data shows 3989 protein coding genes in the M. 
tuberculosis  H37Rv  genome. These genes were subjected to 
BLAST with DEG and 628 genes were found to be essential for 
M. tuberculosis H37Rv. Comparative studies with human were 
performed to find out genes with or without homolog to human. 
Genes those that were homologous to human were neglected as 
they were functionally similar with those of human. Out of 628 
essentials genes, 324 genes lack similarity to the human genome 
in BLASTX homology search and were identified as potential 
candidates for further target based drug development. We 
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manually annotated all the genes having no homolog to human 
and removed hypothetical and uncharacterized genes to refine 
the results. The resulting dataset consist of a target dataset of 135 
potential genes. These were further classified using UNIPROT 
based on functions. The analyzed data shows that of the 135 
targets genes, 25 were involved in amino-acid biosynthesis, 10 in 
cell cycle, 8 in transcription, 8 in RNA Binding and 5 in Protein 
transport (Table 1 in supplementary material). It was also 
observed from UNIPROT results that some target genes are 
involved in multiple functions in different pathways (Table 2 
and Table 3 in supplementary material). 
 
Discussion: 
Tuberculosis (TB) is a major cause of illness and death 
worldwide, especially in Asia and Africa. There is a death due to 
tuberculosis for every 15 seconds (2 million deaths per year) and 
about 8 million individuals develop this disease every year [8]. 
Globally, 9.2 million new cases and 1.7 million deaths from TB 
occurred in 2006, of which 0.7 million cases and 0.2 million 
deaths were in HIV-positive people [3]. The existing drugs have 
several shortcomings, the most important of them being the 
emergence of drug resistance.  Existing ‘front-line’ anti-TB 
drugs include isoniazid and rifampicin. The mechanism of action 
of isoniazid has only become clear in the last few years [9]. 
Isoniazid is a pro-drug, activated intracellularly by the MTB 
catalase/peroxidase, probably to a radical form that irreversibly 
modifies the NAD(H)-binding site of one or more enzymes 
involved in lipid synthesis. InhA [theNADHdependent enoyl 
(acyl carrier protein) reductase] and KasA (the 3-oxoacyl ACP 
synthase) have been demonstrated to be targets for isoniazid [9-
10]. Modifications in the target enzymes and in the activating 
catalase/peroxidase provide the means for MTB to evade the 
antibiotic actions of the drug [11-12].  
 
Rifampicin is a well-characterized inhibitor of DNAdependent 
RNA polymerases. Resistance to rifampicin results from 
mutations in the drug-binding site of the polymerase that do not 
adversely affect the enzyme’s activity [11]. Resistance to other 
major and ‘second-line’ anti-Mtb drugs is now also well known. 
Pyrazinamide (a close relative of nicotinamide) is also a pro-
drug, requiring activation by the enzyme pyrazinamidase. 
Mutation in the relevant pncA  gene affects pyrazinamide 
activation, and resistance may also be facilitated by alteration of 
its transport into the Mtb cell [13]. Streptomycin targets 
translation by associating with ribosomal proteins and the 16 S 
RNA of the ribosome 30 S subunit. Resistance in Mtb arises 
from mutations in the rspL gene (encoding the S12 protein target 
for streptomycin binding) and in conserved loop regions of the 
16 S RNA, encoded by the rrs gene [14]. Ethambutol is known 
to be inhibitory to polyamine function and cell-wall synthesis. 
Mutations in embB, encoding an arabinosyltransferase involved 
in cell-wall biogenesis, are associated with ethambutol 
resistance, but other mechanisms of resistance also appear to be 
operative  [15].  Recently, the second-line anti-Mtb drug 
ethionamide has been shown to require activation by a Mtb 
flavin mono-oxygenase to convert it into the cytotoxic form [16-
17]. Overexpression of InhA was found to confer resistance to 
both isoniazid and ethionamide, revealing an obvious route for 
development of antibiotic resistance in the pathogen [18]. 
 
No new anti-Mtb drugs have been developed for well over 20 
years. In view of the increasing development of resistance to the 
current leading anti-Mtb drugs, novel strategies are desperately 
needed to avert the ‘global catastrophe’ forecast by the WHO. 
The timely determination of the genome sequence of Mtb H37Rv 
by Stewart Cole and co-workers in 1998 provided a much-
needed boost for TB research, elucidating the genetic 
constitution of the pathogen and revealing many novel gene 
products for mechanistic and structural characterization, and as 
potential new drug targets [19].  Therefore, computational 
approach for drug targets identification, specifically for Mtb, can 
produce a list of reliable targets very rapidly. These  methods 
have the advantage of speed, low cost and even more 
importantly, provide a systems view of the whole microbe at a 
time. Since it is generally believed that the genomes of bacteria 
contain both genes with and without homologues to the human 
host. Using computational approach for target identification is 
very quick to produce a desirable list. Here we performed 
database search and found total 3989 genes in the M. 
tuberculosis H37Rv genome, we had annotated all the genes and 
removed all hypothetical genes to refine the results. After 
removing all hypothetical genes, 135 genes have been identified 
as potential drug targets. These genes and their products can be 
targets for future drug development and even screening can be 
done with the available drugs for tuberculosis.  
 
Conclusion: 
Comparative genome analysis of MTB H37Rv and human 
provides a simple framework for integrating the vast amount of 
genomic data that can be used in the drug target identification. 
Drugs that specifically target genes with high homology to the 
host can lead to unwanted toxicity, therefore, finding new ant-
ituberculosis drugs should based on subtractive genome analysis. 
The analysis shows that 628 of the 3989 genes in Mycobacterium 
tuberculosis H37Rv were found to be essential of which 324 
genes lack similarity to the human genome. Subsequently 
hypothetical proteins were removed through manual curation. 
This further resulted in a dataset of 135 proteins with essential 
function and no homology to human.  
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Table 1: Targets and UNIPROT functional assignment  
No. of 
Targets 
Function obtained using UNIPROT  No. of 
Targets 
Function obtained using UNIPROT 
25 Amino-acid  biosynthesis  10 Cell  cycle 
08 Transcription    08 RNA  binding 
05 Protein  transport  04 Translation 
04 ATP  binding  04 Transporter  activity 
04 Nucleotide  Biosynthesis  03 Antibiotic resistance, Cell wall biogenesis/degradation 
03 DNA  repair  03 Electron  transport  chain 
03 DNA  replication  03 Oxido-reductase  activity 
03  Thiamine biosynthesis   03  Riboflavin biosynthesis 
03 Transferase  activity  02 Acyl  transferase 
02 Menaquinone  biosynthesis  02 Cell wall biogenesis/degradation 
02 Pantothenate  biosynthesis  02 DNA  binding 
02 Terpenoid  biosynthesis  01 Antibiotic resistance, folate biosynthesis 
01 Carbohydrate  metabolic  process  01 Cytochrome  complex  assembly 
01  Cobalamin biosynthesis  01  Defense response  
01  Cobalamin biosynthesis, Glutamine 
biosynthesis 
01 DNA  replication,  transcription 
01  Fatty acid Biosynthesis, Oxidation 
reduction 
01 Fatty  acid  biosynthesis 
01 Folate  biosynthesis  01 GTP  metabolic  process 
01  Glutamate biosynthesis, Oxidation 
reduction 
01 Immune  response 
01  Iron ion transport, Oxidation reduction  01  Lipoprotein biosynthetic process 
01  Lipopolysaccharide biosynthetic process  01  Metal Binding, urease activity 
01  Metal ion binding, Trehalose-phosphatase 
activity 
01  Metal ion binding 
01 Methyltransferase  01 Mo-molybdopterin  cofactor biosynthetic process, Sulfur 
metabolic process 
01 Proteolysis  01 Porphyrin  biosynthesis 
01  Respiratory chain complex IV assembly  01  Ribosome biogenesis 
01 Virulence  01 Ribosome  biogenesis,  translation 
 
Table 2: Target genes and UNIPROT data 
S. No.  Gene Name  Locus  Protein ID.  Function obtained from UNIPROT 
1  embC Rv3793 NP_218310  Antibiotic  resistance,  cell wall biogenesis/degradation 
2  embB Rv3795 NP_218312  Antibiotic  resistance,  cell wall biogenesis/degradation 
3  aftA Rv3792 NP_218309  Antibiotic  resistance,  cell wall biogenesis/degradation 
4  folP1 Rv3608c  YP_177997  Antibiotic resistance, folate biosynthesis 
5  cobQ2 Rv3713  NP_218230  Cobalamin biosynthesis,  glutamine biosynthesis 
6  dnaG Rv2343c NP_216859 DNA  replication,  transcription 
7  des Rv0824c YP_177758 Fatty  acid  biosynthesis, oxidation reduction 
8  gltB Rv3859c NP_218376 Glutamate  biosynthesis, oxidation reduction 
9  mbtG Rv2378c  NP_216894  Iron ion transport, oxidation reduction 
10  ureC Rv1850  NP_216366  Metal Binding, urease activity 
11  otsB Rv3372  NP_217889  Metal ion binding, trehalose-phosphatase activity 
12  moaD Rv3112  YP_177928  Mo-molybdopterin cofactor biosynthetic process, sulfur metabolic process 
13  rplJ Rv0651  NP_215165  Ribosome biogenesis, translation 
 
Table 3: Target genes and pathways data 
S. No.  Gene Name Locus  Protein ID.  Function obtained from UNIPROT 
1  embC Rv3793 NP_218310 
2  embB Rv3795 NP_218312 
3  aftA Rv3792 NP_218309 
4  alr Rv3423c NP_217940 
5  pbpB Rv2163c NP_216679 
Cell wall biogenesis/degradation 
6  ftsQ Rv2151c NP_216667 
7  ftsZ Rv2150c NP_216666 
8  ftsK Rv2748c NP_217264 
9  murG Rv2153c NP_216669 
10  mraY Rv2156c NP_216672 
11  ftsX Rv3101c NP_217617 
12  xerD Rv1701 NP_216217 
13  murC Rv2152c NP_216668 
14  murF Rv2157c NP_216673 
Cell cycle 
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15  murD Rv2155c NP_216671 
16  dnaE1 Rv1547 NP_216063 
17  dnaA Rv0001 NP_214515 
18  dnaB Rv0058 NP_214572 
19 dnaG  Rv2343c  NP_216859 
DNA replication 
20 cmk  Rv1712  NP_216228 
21  pyrH Rv2883c NP_217399 
22  thyX Rv2754c NP_217270 
23 nadA  Rv1594  NP_216110 
Nucleotide biosynthesis 
24  folB Rv3607c YP_177996 
25  folP1 Rv3608c YP_177997 
Folate biosynthesis 
26  rpoD Rv2703 NP_217219 
27  mysB Rv2710 NP_217226 
28  nusB Rv2533c NP_217049 
29  nusA Rv2841c NP_217357 
30  mce3R Rv1963c NP_216479 
31  rpoA Rv3457c NP_217974 
32  rpoZ Rv1390 NP_215906 
Transcription 
33  fdxA Rv2007c NP_216523 
34  qcrA Rv2195 NP_216711 
35 qcrC  Rv2194  NP_216710 
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